<a href="https://laohu8.com/S/MRNA">Moderna</a> announces promising early clinical data for mRNA4359 cancer antigen therapy at ESMO 2025
Moderna Inc. has announced new clinical data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab for patients with checkpoint inhibitor-resistant or refractory (CPI-R/R) melanoma. Results from the study, which include clinical, safety, and translational data, will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, scheduled for October 17-21, 2025, in Berlin, Germany. The presentation, titled "Clinical Outcomes and PD-L1 Expression Analyses from a Trial of mRNA-4359 Plus Pembrolizumab in Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma," will be delivered by Prof. David J. Pinato on October 17, 2025. mRNA-4359 is an investigational immune-evasion targeted cancer antigen therapy designed to encode epitopes of two immune escape pathways, PD-L1 and IDO1, with the aim of eliciting antigen-specific T cell responses. Moderna reports that mRNA-4359 in combination with pembrolizumab has shown a consistently manageable safety profile, with no new immune-related adverse events observed. The therapy continues to be evaluated in an ongoing Phase 1/2 trial for patients with advanced melanoma and non-small cell lung cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1085109) on October 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.